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Abstract The activity of bovine colostrum CMP-NeuAc: 
Gal/31--~4GIcNAcl3-R c~2-->6-sialyltransferase (a6-NenAcT) 
toward oligosaccharides that form part of complex-type, N- 
linked glycans appears significantly reduced when a bisecting 
GlcNAc residue or additional branches are present, or when core 
GIcNAc residues are absent. By contrast human placenta CMP- 
NeuAc: Gall~l -->4GicNAc/]-R a2--> 3-sialyltransferase (a3- 
NeuAcT) is much less sensitive to structural variations in these 
acceptors. Furthermore the a3-NeuAcT shows a much higher 
activity than the c~6-NeuAcT with oligosaccharides that form 
part of linear and branched iactosaminoglycan extensions. These 
results indicate that, in tissues that express both enzymes, branch- 
ing and lactosaminoglycan formation of N-linked glycans will 
cause a shift from termination with ~2-->6-1inked sialic acid to 
termination with a2-->3-1inked sialic acid residues. These find- 
ings provide an enzymatic basis for the sialic acid linkage-type 
patterns found on the oligosaccharide chains of N-glycoproteins. 
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I. Introduction 
Many complex, N-acetyllactosamine-type oligosaccharides 
occurring on N-glycoproteins contain sialic acid in c~2---> 3- or 
c~2 ~ 6-glycosidic linkage at their non-reducing termini [1,2]. It 
has appeared that ~2--* 3-1inked sialic acid is more frequently 
present on tri- and tetra-branched glycans, whereas ~2~6-  
linked sialic acid is predominant on di-antennary oligosac- 
charides (reviewed in [3]). A minimum of two different sia- 
lyltransferases is required for the synthesis of these linkages. So 
far only one sialyltransferase has been described that catalyses 
the transfer of sialic acid in ~2 ~ 6-linkage to Gal of the N- 
acetyllactosamine units of glycoprotein glycans. This enzyme, 
regardless of its species or tissue origin, is very specific for 
Galfll--*4GlcNAc and acts with very low activity on 
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Abbreviations: CMP-NeuAc; Cytidine 5'-monophospho-N-acetylneu- 
raminic acid; NeuAc, N-acetylneuraminic acid; GAIT, galactosyltrans- 
ferase; GlcNAcT, N-acetylglucosaminyltransferase; ~6-NeuAcT, 
CMP-NeuAc: Galfl 1 --* 4GlcNAcfl-R c~2 --~ 6-sialyltransferase (EC 
2.4.99.1); c~3-NeuAcT, CMP-NeuAc: Galfll --~ 4GIcNAcfl-R ~2 --> 3- 
sialyltransferase (EC 2.4.99.6). 
Galfll-->3GlcNAc and Galfll--->3GalNAc, if at all [4,5]. This 
sialyltransferase is highly expressed in human [6,7] and rat 
[8 11] liver. On the other hand two ~3-NeuAcTs have been 
described that are capable to catalize the synthesis of a 
NeuAc~2---> 3Galfll ~ 4GIcNAc sequence. In human placenta 
~3-NeuAcT was identified [12] that was later shown to have a 
high preference for Galf l l -~4GlcNAc [13]. Recently a sia- 
lyltransferase has been cloned that probably corresponds to 
this placenta enzyme [14,15]. Interestingly, the recombinant 
form of this enzyme is also capable of acting on Galfll--~ 
3GalNAc [15] and (to a much lesser extent) on Ga l f l l~  
3GlcNAc [14,15]. Northern analysis revealed high mRNA lev- 
els for this enzyme in human placenta [7]. Another c~3-NeuAcT 
acting on Galfll ---~ 4GlcNAc was first purified from rat liver [9]. 
The natural as well as the recombinant form of this enzyme, 
however, has a high preference for acceptor substrates contain- 
ing a terminal Galfll ~3GlcNAc  unit [16,17]. 
So far oligosaccharide acceptor specificities for these en- 
zymes have been mainly determined with small, linear struc- 
tures. The results obtained in these studies, therefore, did not 
provide an explanation for the specific ~2--* 3/ct2--~ 6-sialyla- 
tion patterns occurring on N-linked oligosaccharide chains. We 
have recently determined the acceptor specificity of the c~3- 
NeuAcT from placenta with di-, tri- and tetra-antennary gl can 
structures [13]. In this study these data are complemented with 
the acceptor properties of these branched substrates for the 
~6-NeuAcT isolated from bovine colostrum. Comparison of 
the activities of both sialyltransferases indicates that branching 
of N-linked glycans as well as lactosaminoglycan formation, 
which are controlled by the action of distinct N-acetylglu- 
cosaminyltransferases, r ult in a shift from termination with 
~2 --+ 6-1inked sialic acid to termination with c~2 --~ 3-1inked sialic 
acid residues. 
2. Experimental 
2.1. Materials 
CMP-[14C]NcuAc (specific radioactivity 4.1 Ci/mol) was obtained 
from New England Nuclear (Boston, MA) and was diluted with unla- 
belled CMP-NeuAc [18] to the desired specific activity. The various 
oligosaccharides, which were used to examine the acceptor specificities 
of the sialyltransferases, were kindly donated by the following persons: 
compounds 1, 15, 16 and 17 by Drs. S. David, J. Alais and A. Veyri6res 
(Universit6 Paris-Sud, Orsay, France); compounds 2, 3, 5, 7, 9, 11 and 
13 by Dr. J. L6nngren (University of Stockholm, Stockholm, Sweden); 
compound 18 by Dr. H. L6nn (Biocarb, Lund, Sweden) and com- 
pounds 4, 6, 8, 10, 12 and 14 by Drs. G. Strecker and J.C. Michalski 
(Universit6 de Lille, Villeneuve d'Ascq, France). 
2.2. Enzymes and activity assays 
~6-NeuAcT was partially purified from bovine colostrum as de- 
scribed previously [19]. c~3-NeuAcT was prepared from human placenta 
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as reported earlier [13]. This enzyme was stored as a microsomal pellet 
in aliquots at -20°C, and was resuspended directly before use, 
The incubation mixtures for the assay of ~6-NeuAcT activity toward 
the various acceptor substrates contained in a volume of 50 ,ul: an 
amount of oligosaccharide having 50 nmol terminal Gal residues, 25.5 
nmol CMP-[14C]NeuAc (1.05 Ci/mol), 5.0/~mol of sodium cacodylate 
pH 6.7, 0.043 mU ~z6-NeuAcT (16 ¢tg of protein) and 0.4/tl glycerol. 
Incubation mixtures for c~3-NeuAcT contained in a volume of 50 ¢tl: 
Table 1 
Acceptor specificity of bovine colostrum ~6-NeuAcT and human placenta c~3-NeuAcT toward oligosaccharide acceptors that form part of N-linked 
glycans 
Oligosaccharide Relative activity (%) 
~6-NeuAcT a3-NeuAcT 
1. Galfll --~ 4GlcNAc 29 135 
2. Galfll ---~ 4GlcNAc]31 ---> 2Man 69 157 
3. Galfl l  --* 4GlcNAcfll --* 6Man 44 153 
4. Galfll --* 4GlcNAcfl l  ~ 2Man~l --* 6Man/31 ~4GlcNAc  18 127 
5. Galfll ~4GlcNAcf l l  ~2Manc~l \  
6 
Man 39 116 
3 
Galfll ---) 4GlcNAcfl l  ---~ 2Man~ 1 7 
6. GalB1 ~ 4GlcNAcfll ~ 2Mantel 
6 
Man,81 --> 4GIcNAc 100 100 
3 
Galfl I --> 4GlcNAcfl 1 --> 2Man~ 1 7 
7. Galfll ---> 4GlcNAcfll ---~ 2Man~l 
\ 
6 
GlcNAcfll --~ 4Man 46 66 
3 
Gal~ 1 ~ 4GlcNAc~I ~ 2Man~ 1 7 
8. Galfll ---~ 4GlcNAc~I --> 2Man~l 
\ 
6 
GlcNAcfl 1 --> 4Manfl 1 --> 4GlcNAc 66 48 
3 
Galfll --~ 4GlcNAc~ 1 ~ 2Man~ 1/" 
9. Galfll ---> 4GlcNAcfl l  --> 2Man~l 
\ 
6 
Man 29 122 
3 
Galfl I ~ 4GlcNAcfll --~ 2Man~ 1 7 
4 
Galfl 1 --~ 4GlcNAc~ 1 7 
11. Galfl l  ~ 4GlcNAcfl l  ~ 2Man~l 
\ 
6 
Man~l  ~ 4GIcNAc 61 132 
3 
Gal~ 1 ~ 4GlcNAc~I ~ 2Man~ 1 7 
4 
Galfl 1 ~ 4GlcNAcfl 1 7 
11. Galfll ---> 4GlcNAcfll,N 
6 
Galfl l  --> 4GlcNAcfl I ~ 2Man~ 1 
\ 
6 
Man 3 75 
3 
Galfl l  ~ 4GlcNAcfll --> 2Mantel f 
12. Gal~l  ~4GlcNAc~I \  
6 
Galfll --> 4GlcNAc~I ~ 2Man~l 
\ 
6 
Manfl l  --~ 4GIcNAc 35 89 
3 
Galfll ~ 4GlcNAcfl 1 ~ 2Manc~ 17 
282 
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Oligosaccharide Relative activity (%) 
~6-NeuAcT cz3-NeuAcT 
13. Galfll --) 4GlcNAcfll\ 
6 
Galfll -~ 4GlcNAcfll --+ 2Man~l \ 
6 
Man 
3 
Galfll --+ 4GlcNAcfll ---~ 2Man~l "/" 
4 
Galfll ---) 4GlcNAcfll "/' 
14. Galfll --~ 4GlcNAcfll\ 
6 
Galfll --) 4GlcNAcfl 1 -~ 2Man, l \  
6 
Manfll ~ 4GIcNAc 
3 
Galfll ~ 4GIcNAcfll --~ 2Man~l/" 
4 
Galfll --* 4GlcNAcfll /
7 68 
23 83 
Acceptors were present at an amount as to give a concentration f terminal Gal residues of 1 mM. The activities were assayed as described in section 
2. The relative activities with each acceptor are expressed as a percentage of the incorporation btained with the diantennary oligosaccharide 6, which 
amounted 2.61 nmol. mg-~protein - rain -l for ~6-NeuAcT and 25.3 pmol.mg-lprotein - min i for ~3-NeuAcT. 
oligosaccharide (50 nmol terminal Gal), 25.5 nmol CMP-[~4C]NeuAc 
(1.05 Ci/mol), 5.0 gtmol of sodium cacodylate pH 6.7, Triton X-100 
(final concentration 0.1% by vol) and placenta microsomes (0.051 mU 
~3-NeuAcT, 2 mg of protein). The mixtures were incubated at37°C for 
30-45 min whereafter the incubations were stopped by cooling on ice 
and dilution with 100 pl of ice cold H20. When present, microsomal 
material was removed by centrifugation. I corporation of [14C]NeuAc 
into the acceptors was assayed by applying the mixtures to a column 
(1.6 x 200 cm) of Bio-Gel P-4 (200-400 mesh) equilibrated and eluted 
with 50 mM ammonium acetate at pH 5.2 and 37°C, at a flow rate of 
8 ml/h. The incorporation of [14C]NeuAc was calculated from the radi- 
oactivity in the fractions containing the product. Under the incubation 
conditions employed CMP-NeuAc and oligosaccharide substrates were 
present at saturating concentrations [3,13,20]. Because of the limited 
availability of the acceptors it was, however, not possible to estimate 
Km and Vm,x values for the individual oligosaccharides. Therefore only 
relative rates (kinetic efficiencies) are given. 
3. Results and discussion 
A number of oligosaccharides, that form part of complex, 
N-acetyllactosamine-type N-linked glycans, were tested as ac- 
ceptors for bovine colostrum a6-NeuAcT and human placenta 
a3-NeuAcT. All structures possessed at least one terminal 
Galfl--+4GlcNAc unit as a minimum acceptor equirement for 
these enzymes. They differed, however, in the underlying se- 
quence as well as in the degree of branching. It appears that the 
a6-NeuAcT is much more sensitive to changes in the structure 
of the acceptors than the ~3-NeuAcT (Table 1). The activity of 
the latter enzyme varies by a factor of 3, whereas this variation 
amounts up to a factor of 30 for the ~6-NeuAcT, 
The best acceptor substrate for the a6-NeuAcT is the di- 
antennary oligosaccharide 6. It has been described that the 
~6-NeuAcT highly prefers the Gal at the Manal---~3Man 
branch for attachment of a sialic acid residue and that the rate 
of sialic acid attachment in ~2~6-1inkage to the Gal at the 
Manal- -+6Man branch is comparatively low [3,20]. This 
might explain why oligosaccharide 4, which represents the 
Man~l- -+6Man branch of N-linked glycans, is a rel- 
atively poor acceptor. The ~3-NeuAcT does not show any 
preference for either branch of the di-antennary substrate [13], 
which is consistent with the good acceptor properties of oligo- 
saccharide 4 for the latter enzyme. 
Bisecting GlcNAc residues are the result of action of 
GlcNAcT III [21]. When, as in compound 8, such a residue is 
present, both the ~6-NeuAcT and the ~3-NeuAcT show a lower 
activity (Table 1). Similarly the presence of a bisecting GlcNAc 
residue has previously been demonstrated to block the reac- 
tions catalyzed by mannosidase lI, GlcNAcT II and IV, and 
~6-fucosyltransferase [21,22] and to partially inhibit those cata- 
lyzed by GIcNAcT V [23], fl4-GalY [24,25], ~3-fucosyltrans- 
ferase (D.H. van den Eijnden and W.E.C.M. Schiphorst, un- 
published results), ~3-GalT [23] and fl3-GlcNAcT (i-enzyme) 
[26]. This suggests that a bisecting GlcNAc residue has a pro- 
found effect on the conformation of the oligosaccharide struc- 
ture resulting in an interference with most of the subsequent 
processing steps of protein N-glycosylation. 
Action of GlcNAcT IV results in the formation of oligosac- 
charides with a GlcNAcfl 1 --~ 2(GlcNAcfl I --~ 4)Man~ 1--* 3Man 
branching point [21,22]. The tri-antennary oligosaccharide 10, 
containing such a branching point, shows a reduced acceptor 
property for the ~6-NeuAcT as compared to that of the di- 
antennary oligosaccharide 6 (Table 1). By contrast, the pres- 
ence of this GlcNAcfl 1 ~ 4-branch improves the acceptor prop- 
erty for the ~3-NeuAcT. The isomer of this structure, the 
tri '-antennary oligosaccharide 12, possesses a GlcNAcfll--~ 
2(GlcNAcfl l--~6)Man~l--~6Man branching point which re- 
sults from the action of GlcNAcT V [22,27]. The presence of 
this branch has an even stronger negative ffect on the acceptor 
property for the ~6-NeuAcT, whereas the activities of the ~3- 
NeuAcT with this substrate and the di-antennary oligosac- 
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Table 2 
Acceptor specificity of bovine colostrum c~6-NeuAcT and human placenta c~3-NeuAcT toward oligosaccbaride acceptors that are structurally related 
to linear (blood group i-active) and branched (blood group I-active) polylactosaminoglycans 
Oligosaccharide Relative activity (%) 
~6-NeuAcT c~3-NeuAcT 
15. Galfll --~ 4GlcNAcfll --* 3Gal 55 161 
16. Galfll --* 4GlcNAcfll ~ 3Galfll --+ 4GIcNAc 33 133 
17. Galfll --~4GIcNAcfll N
6 
Gal 21 78 
3 
Galfll --~ 4GlcNAcfl 1/" 
18. Galfll ---~ 4GlcNAefll\ 
6 
Galfll ~ 4Glc 25 109 
3 
Galfll --~ 4GlcNAcfll/" 
Acceptors were present in an amount as to yield a concentration f terminal Gal residues of 1 mM. The activities were assayed as described insection 
2. The relative activities with each acceptor are expressed as a percentage of the incorporation obtained with the diantennary oligosaccharide 6 
(Table 1). 
charide 6 are comparable. The results obtained with tetra- 
antennary oligosaccharide 14, which contains both additional 
branches, are in line with those of oligosaccharides 10and 12 
(Table 1). These data indicate that in tissues that express both 
sialyltransferases, such as human liver [6,7], the sialic acid link- 
age-type pattern of c~2 --~ 3- and c~2--~ 6-1inked sialic acid on the 
glycoprotein products is not only dependent on the relative 
expression levels of these enzymes, but also on whether or not 
the oligosaccharide structures have been acted upon by 
GIcNAcT IV and V earlier in the glycosylation process. 
Branching due to the action of these GlcNAcTs appears to 
result in a shift from termination with c~2 ~ 6-1inked sialic acid 
to termination with c~2~3-1inked sialic acid residues. This 
mechanism thus provides an enzymatic basis for the sialic acid 
linkage-type patterns found on the oligosaccharides on many 
N-glycoproteins [3]as well as on sialo-oligosaccharides isolated 
from urine [28] and placenta [29] of galactosialidosis patients. 
Glycoproteins containing sialic acid in both linkage types carry 
most of the c~2--+ 3-1inked sialic acid residues on tri-, tri'-, and 
tetra-antennary oligosaccharides, whereas the di-antennary 
glycans predominantly contain sialic acid in ~2---~6-1inkage 
[30 331 .
An interesting property of the c~6-NeuAcT is observed when 
activities are compared toward oligosaccharides with or with- 
out a GlcNAc residue at their reducing end. Comparison of 
such oligosaccharide pairs (5/6, 7/8, 9/10, 11/12, 13/14) shows 
that the absence of a reducing GlcNAc results in a strongly 
decreased activity of the ~6-NeuAcT (Table 1). By contrast the 
activity of the ~3-NeuAcT is essentially unaffected by the ab- 
sence of such a residue. It is possible that the better acceptor 
property for the ~z6-NeuAcT of oligosaccharides, in which a 
reducing GlcNAc is present, is simply due to the fact that this 
residue keeps the subterminal Man in fl-anomeric onfigura- 
tion. However, this does not explain why the magnitude of the 
effect is not the same for all oligosaccharide pairs. Previously 
it has been shown that a minimum of one core GlcNAc is 
absolutely required to preserve the preference of the ~6- 
NeuAcT for the Gal at the Mantel ~3Man branch [20]. It was 
proposed that the core GlcNAc residue, such as present in 
oligosaccharide 6, 8, 10, 12 and 14 forms an essential part of 
a sequence that is recognized by the ~6-NeuAcT in a lectin-like 
way. This would imply that this enzyme has either a second 
carbohydrate r cognizing domain in addition to the one that 
interacts directly with the Galfll --~4GlcNAc unit of the gly- 
cans, or that it has a large, extended binding site that recog- 
nizes the entire Galfll ~ 4GlcNAcfll --+ 2Manc~ 1 --~ 3Manfll -~ 
4-G1 cNAc sequence of these glycans. Alternatively, a minimum 
of one core GlcNAc residue might be essential for keeping the 
Man~l ~3Man branch in an orientation that allows optimal 
binding to the c~6-NeuAcT. Comparison of the results obtained 
with the c~6-NeuAcT and the c~3-NeuAcT suggests that these 
enzymes recognize their acceptor substrates ina fundamentally 
different way. This is consistent with the fact that, apart from 
the 'sialyl motit ", that is involved in binding of the CMP- 
NeuAc donor-substrate [34], and a second small region of 
sequence similarity [35], these enzymes are non-homologous 
[14,15]. 
As discussed above, action of GlcNAcT V yields branched 
structures that, after fl4-galactosylation, are acted upon by the 
c~6-NeuAcT at a much lower rate than by the c~3-NeuAcT. On 
the other hand, such branched structures have been demon- 
strated to be preferred acceptor substrates for fl3-GlcNAcT, 
which enzyme is involved in the initiation as well as the elonga- 
tion of N-linked lactosaminoglycan chains [26]. Action of 
GlcNAcT V thus promotes lactosaminoglycan hain formation 
of such chains, while it leads to inhibition of ~6-sialylation 
leaving ~3-sialylation essentially unimpaired. In Table 2 it is 
shown that several representative, partial structures of linear 
and branched lactosaminoglycan chains are better substrates 
for the c~3-NeuAcT than for the c~6-NeuAcT. Lactosaminogly- 
can formation thus reinforces the effect that branching by 
GIcNAcT V has on the sialic acid linkage type patterns of 
N-glycoproteins. 
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